Clinical Trial

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-12-10; most recent amendment 2026-07-17.
Trial Details
NCT Number NCT07300241
Lead Sponsor Neomorph, Inc
Conditions Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC, VHL-Associated Clear Cell Renal Cell Carcinoma, VHL-Associated Renal Cell Carcinoma, Kidney Cancer Metastatic +1 more
Enrollment 30 participants
Start Date 2025-12-19
Primary Completion 2027-01 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-03